Spencer Campbell, MD
Endocrinology, Diabetes & Metabolism · Lawton, OKNPI 1376038539
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,526 of the $3,680 with a category attached, or 68.6%. 24 manufacturers reported payments, led by Medtronic at 37.9% of the total.
Across 129 payments — averaging $28.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Corcept Therapeutics$564
- Dexcom, Inc.$254
- Lilly USA, LLC$239
- Mannkind Corporation$186
- Abbott$172
- plus $870 from 18 others
What the payments were for
- Travel & lodging$1,05529%
- Food & beverage$2,52669%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,396 |
| Corcept Therapeutics | 27 | $564 |
| Dexcom, Inc. | 15 | $254 |
| Lilly USA, LLC | 13 | $239 |
| Mannkind Corporation | 10 | $186 |
| Abbott | 8 | $172 |
| Xeris Pharmaceuticals, Inc. | 9 | $165 |
| Novo Nordisk | 5 | $104 |
| Novartis | 3 | $79 |
| Insulet Corporation | 3 | $75 |
| Tandem Diabetes Care, Inc. | 3 | $62 |
| BETA Bionics, Inc. | 3 | $56 |
| Bayer | 1 | $56 |
| Pfizer | 2 | $36 |
| Amgen | 2 | $35 |
| Antares Pharma, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,094
How this compares
$3,680 in reported general payments places this provider in the 55th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 202 | $240,447 |
| OzempicSemaglutide | 165 | $199,511 |
| TrulicityDulaglutide | 60 | $66,485 |
| JardianceEmpagliflozin | 28 | $33,392 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $28,131 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $27,615 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $24,290 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $19,868 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $16,827 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $15,464 |
| NovologInsulin Aspart | 21 | $10,029 |
| Novolog FlexpenInsulin Aspart | 33 | $10,013 |
| Gvoke Hypopen 2-PackGlucagon | 15 | $9,651 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $8,643 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $7,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $239 | $313,753287 claims |
| Novo NordiskOzempic, Novolog | $104 | $209,540186 claims |
| Boehringer IngelheimJardiance | $17 | $33,39228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Lawton
- Nilma MalikLawton$738
- Cassie SmithEdmond$629K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Matthew DraelosEdmond$110K
- Christian MangrumOklahoma City$54K
- Vaqar AhmadMidwest City$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Robert ScofieldOklahoma City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.